12:00 AM
 | 
Dec 03, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

PA8140: Phase I data

Pozen said data from the Phase I PA8140-102 trial showed that PA8140 was bioequivalent to 81 mg enteric-coated aspirin based on undisclosed pre-specified criteria from FDA. PA8140 also had comparable bioavailability to enteric-coated aspirin. Pozen said it has...

Read the full 167 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >